Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 299, Issue -, Pages 98-106Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2016.08.018
Keywords
Alzheimer's disease; A beta; Tau; Neuroinflammation; gamma-Secretase; GSK-3; Diosmin
Categories
Funding
- NIH/NIA [R21AG049477]
- NIH/NCCIH [R01AT007411]
- USF Health Byrd Institute Small Grant Program
- Silver Endowment
Ask authors/readers for more resources
Naturally-occurring bioactive flavonoids such as diosmin significantly reduces amyloid beta (A beta) associated pathology in Alzheimer's disease (AD) mouse models. In the present study, oral administration of diosmin reduced cerebral A beta oligomer levels, tau-hyperphosphorylation and cognitive impairment in the 3xTg-AD mouse model through glycogen synthase kinase-3 (GSK-3) and transient receptor potential canonical 6-related mechanisms. Diosmetin, one major bioactive metabolite of diosmin, increased inhibitory GSK-3 beta phosphorylation, while selectively reducing gamma-secretase activity, A beta generation, tau hyperphosphorylation and pro-inflammatory activation of microglia in vitro, without altering Notch processing. Therefore, both diosmin and diosmetin could be considered as potential candidates for novel anti-AD therapy. (C) 2016 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available